ClinicalTrials.gg
CompletedNCT03217409Updated Sep 23, 2019

A Study to Compare Rosuvastatin/Ezetimibe and Rosuvastatin in Patients With Diabetes Mellitus and Hypercholesterolemia

A Phase 4 interventional study of Rosuvastatin+Ezetimibe and Rosuvastatin in Diabetes Mellitus and Hypercholesterolemia, sponsored by Yuhan Corporation. Completed at 4 sites in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-09-23.

Sponsored by Yuhan Corporation · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing rosuvastatin in Diabetes Mellitus — 1 open to participants now, 1 under way, none of them phase 3. rosuvastatin · Diabetes Mellitus.

Enrollment
12th of 17
85 · median 108
Started
2017
with 1 other
Phase 4
9 of 17
none open now
Registered
15th of 17
by date

Among the 17 studies testing rosuvastatin in Diabetes Mellitus, this one is the 12th largest by enrollment, is one of 2 that started in 2017, is one of 9 in phase 4, and was the 15th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,074 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

1 of the 17 studies testing rosuvastatin in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 650 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 197 (30%) stop at 75 or younger; 88 take children under 18; 183 take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing rosuvastatin in Diabetes Mellitus, or all of them as a file.
02

Study summary

A Study to Compare Rosuvastatin/Ezetimibe Combination and Monotherapy in Patients with Diabetes Mellitus and Hypercholesterolemia.

Read the detailed description

This trial is conducted to compare the efficacy and safety between Rosuvastatin/Ezetimibe combination and Rosuvastatin monotherapy in patients with Diabetes Mellitus and Hypercholesterolemia for 8 weeks.

03

Conditions studied

  • Diabetes Mellitus and Hypercholesterolemia
04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects ≥ 19 or ≤ 75 years of age
  • Subjects undergoing treatment for type 2 diabetes
  • Subjects undergoing treatment of statin for hypercholesterolemia
  • Fasting LDL-C ≤ 250mg/dL at the screening visit
  • Fasting LDL-C ≥70mg/dL or ≤ 160mg/dL at the randomization visit
  • Fasting TG\<500mg/dL

Exclusion criteria

Exclusion Criteria:

  • Subjects with reaction to Statin and Ezetimibe
  • Subjects with severe kidney disease
  • Subjects with positive result at the screening
  • Pregnant or breast-feeding subjects
  • Subjects with taking any medication affecting level of LDL (Fenofibrate, Omega 3 fatty aicd etc.)
  • Insulin-treated Subjects
  • Other exclusions applied
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    Rosuvastatin+Ezetimibe

    Rosuvastatin 5mg+Ezetimibe 10mg Rosuvamibe ® Tablet, 1T, Once a day/8week

    Drug: Rosuvastatin+Ezetimibe

  • Active comparator
    Rosuvastatin

    Rosuvastatin 5mg Monorova ® Tablet, 1T, Once a day/8week

    Drug: Rosuvastatin

Interventions

  • DrugRosuvastatin+Ezetimibe

    Drug pages: Rosuvastatin · Ezetimibe

    Rosuvastatin 5mg+Ezetimibe 10mg

    Also known as: Rosuvamibe ® 10/5mg

  • Rosuvastatin 5Mg Tablet

    Also known as: Monorova ® 5mg

06

What researchers measure

Primary outcomes

  1. Low density lipoprotein cholesterol (LDL-C) (%)

    The rate of change(%) of LDL-C at Week 8 compared to the baseline

    Time frame: baseline, Week 8

Secondary outcomes

  1. Low density lipoprotein cholesterol (LDL-C) (100mg/dL)

    The ratio of patients who reached the treatment target (100mg/dL) of LDL-C at Week 8 compared to the baseline

    Time frame: baseline, Week 8

  2. HbA1C, Glycated albumin, Homeostasis model assessment Insulin resistance(HOMA-IR), Homeostasis model assessment ß cell(HOMA-ß) resistance(HOMA-IR), Homeostasis model assessment ß cell(HOMA-ß)

    Variation of HbA1C, Glycated albumin, Homeostasis model assessment Insulin resistance(HOMA-IR), Homeostasis model assessment ß cell(HOMA-ß) at Week 8 compared to the baseline resistance(HOMA-IR), Homeostasis model assessment ß cell(HOMA-ß) change form the baseline at Week 8

    Time frame: baseline, Week 8

  3. LDL-C, Non HDL-C, HDL-C, Triglyceride(TG), Total cholesterol(TC), Apolipoprotein A1, Apolipoprotein B, Lipid ratios (LDL-C/HDL-C, TC/HDL-C, Non- HDL-C/HDL-C) Apolipoprotein A1, Apolipoprotein B, Lipid ratios (LDL-C/HDL-C, TC/HDL-C, Non- HDL-C/HDL-C)

    Variation of LDL-C, Non HDL-C, HDL-C, Triglyceride(TG), Total cholesterol(TC), Apolipoprotein A1, Apolipoprotein B, Lipid ratios (LDL-C/HDL-C, TC/HDL-C, Non- HDL-C/HDL-C) at Week 8 compared to the baseline Apolipoprotein A1, Apolipoprotein B, Lipid ratios (LDL-C/HDL-C, TC/HDL-C, Non- HDL-C/HDL-C) change form the base line at Week 8

    Time frame: baseline, Week 8

  4. Thiobarbituric acid reactive substances(TBARs)

    Absolute value change of Thiobarbituric acid reactive substances(TBARs) at Week 8 compared to baseline to baseline.

    Time frame: baseline, Week 8

  5. Fibroblast Growth Factor 21

    Absolute value change of Fibroblast Growth Factor 21 at Week 8 compared to baseline.

    Time frame: baseline, Week 8

07

Study locations

4 sites
  • Soon Chun Hyang University Hospital Cheonan
    Cheonan, Korea, Republic of
  • Soon Chun Hyang University Hospital Gumi
    Gumi, Korea, Republic of
  • Soon Chun Hyang University Hospital Bucheon
    Gyeonggi-do, Korea, Republic of
  • Soon Chun Hyang University Hospital Seoul
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Apr 2019, 19 months.

Of 48 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 22. This study's 19 months is above that.

Counting every sponsor, half of 197 studies reached it within 24 months; a quarter within 13 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2017
First posted
Jul 14, 2017
StartActual
Aug 10, 2017
Primary completionActual
Apr 3, 2019
CompletionActual
May 23, 2019
Last update
Sep 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03217409
Lead sponsor
Yuhan Corporation
Collaborators
Linical Korea
Responsible party
Sponsor
First posted
Jul 14, 2017
Start date
Aug 10, 2017
Primary completion
Apr 3, 2019
Completion
May 23, 2019
Last update
Sep 23, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosuvastatin · Ezetimibe

Start the discussion